The project database enables us to study a group of 974 Multiple Myeloma patients of which we have microarray-based gene expression data and a subgroup of 272 individuals for which we presently also have Next Generation Sequencing information available. This is a very valuable database because it consists of a large group of MM patients with high quality clinical annotation, genetic information, treatment data and associated survival metrics. Combining all this information empowered the project team to drive the bioinformatics discovery of predictive biomarkers (Task 3.2) and as described within D3.2 Bioinformatics analysis report, D4.1 Treatment decision matrix and D8.2 Scientific articles for peer-reviewed journals, we succeed in this effort. Moreover, also self-reported quality of life data is available for 377 European MM patients.